latest news releases from the newsroom
Rabobank Calls For Sustainable Energy Programme
UTRECHT, The Netherlands, Dec. 7, 2004 (PRIMEZONE) -- "The Dutch government should vigorously promote the transition to alternative sources of energy and develop a sustainable energy conservation programme. Both measures would reduce CO2 emissions and the economic dependence on fossil fuels, which primarily come from politically unstable regions and represent finite supplies." Mr H. (Bert) Heemskerk, Chairman of the Executive Board of Rabobank, put forward this view during the presentation of the economic outlook for 2005 on Tuesday, December 7.
LaserMonks Expand into Office Products
SPARTA, Wis, Dec. 7, 2004 (PRIMEZONE) -- LaserMonks, the online provider of printing and imaging supplies at greatly reduced prices for businesses, educational institutions and non-profit organizations, announced the addition of 35,000 office supply items to its core e-business of ink, printer and toner cartridges. The product expansion follows exponential growth, from gross sales of $2,000 in 2002, to gross sales of $2.5 million in 2004.
eLocity Inc.: Pre-Open Stock Alerts For; DYSP, VIVI, MBAH, AOC
SARASOTA, Fla., Dec. 7, 2004 (PRIMEZONE) -- eLocity's velocity stocks to watch for today are; Day Spas of America, Inc. (Pink Sheets:DYSP), Viva International, Inc. (OTCBB:VIVI), MBA Holdings (OTCBB:MBAH) and AON Corporation (NYSE:AOC).
Advance Nanotech, Inc.
Advance Nanotech Portfolio Company Successfully Completes Testing On Its First Nanofabricated Chemical And Explosive Sensor
NEW YORK, Dec. 7, 2004 (PRIMEZONE) -- Owlstone Limited, a subsidiary of Advance Nanotech, Inc., (OTCBB:AVNA) has successfully tested its first nanofabricated chemical and explosive sensor, taking it one step closer to its vision of installing a detection system in trains, airports, financial institutes, government buildings, and indeed, anywhere at threat from chemical or explosive attack.
BSD Medical Corporation
FDA Grants BSD Medical IDE Approval to Enhance High-end Cancer Treatment System
SALT LAKE CITY, Dec. 7, 2004 (PRIMEZONE) -- BSD Medical Corp. (OTCBB:BSDM) today announced that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) approval for several enhancements to the BSD-2000 cancer treatment system. BSD considers these enhancements crucial to the company's strategic marketing plan for future commercial introduction of the BSD-2000 product line. The approval includes software and hardware upgrades as well as modifications that will allow substantial cost reductions in producing the system.